U.S., April 30 -- ClinicalTrials.gov registry received information related to the study (NCT07555106) titled 'Dapagliflozin in Living-Donor Kidney Transplant Recipients' on March 05.
Brief Summary: This randomized, open-label, single-center clinical trial aims to evaluate the effect of dapagliflozin on kidney allograft function in adult recipients of a first living-donor kidney transplant. Participants will be randomized to receive dapagliflozin 10 mg daily starting 4 weeks after transplantation or standard care without SGLT2 inhibitor therapy. The primary outcomes include changes in estimated glomerular filtration rate (eGFR) and albuminuria over 12 months. Secondary outcomes include kidney graft histology findings, oxidative stress bioma...